<DOC>
	<DOCNO>NCT00003345</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine cisplatin irinotecan treating patient ovarian , fallopian tube , peritoneal cancer .</brief_summary>
	<brief_title>Cisplatin Plus Irinotecan Treating Patients With Ovarian , Fallopian Tube , Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate antitumor effect weekly cisplatin irinotecan patient suboptimally debulked ovarian , fallopian tube , peritoneal cancer persistently elevate serum value CA125 3 course standard therapy paclitaxel either carboplatin cisplatin . II . Evaluate toxicity , qualitative quantitative , regimen patient population . III . Evaluate quality life patient . OUTLINE : Patients receive cisplatin IV 30 minute follow irinotecan IV 90 minute . Treatment administer weekly 4 week ( day 1 , 8 , 15 , 22 ) follow 2 week rest . Patients receive least 3 course ( 18 week ) therapy absence disease progression unacceptable toxicity . If patient demonstrate complete response treatment , encourage undergo second-look laparoscopy laparotomy . Quality life assess treatment , first course , every 2 course therapy . Patients follow 30 day last treatment survival . PROJECTED ACCRUAL : There 12-35 patient accrue study 18-24 month .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm epithelial carcinoma ovary , fallopian tube , peritoneum At least 3 prior course standard platinumpaclitaxel regimen Patients taxane allergy may enter study 3 course platinum base treatment CA125 least 35 measure within 30 day commencement treatment Measurable disease require No CNS metastases , carcinomatous meningitis interstitial pulmonary fibrosis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Calcium le 12.0 mg/dL Cardiovascular : No unstable angina No New York Heart Association grade III IV cardiac disease Pulmonary : See Disease Characteristics Other : No active uncontrolled infection No history seizures No known Gilbert 's Disease No medical psychiatric condition make patient poor risk participation study Not pregnant lactate Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy Chemotherapy : No prior irinotecan topotecan Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy pelvis Surgery : At least 4 week since prior surgery recover Other : No concurrent phenytoin , phenobarbital , antiepileptic prophylaxis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>